Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-549 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00427 | uM | 5909.085 | 1.0345 | 1.0221 | 3.0853 | |
| BT-549 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0213 | uM | 5909.085 | 0.9812 | 0.9877 | 3.0853 | |
| BT-549 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.107 | uM | 5909.085 | 1.1191 | 1.0743 | 3.0853 | |
| BT-549 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.533 | uM | 5909.085 | 1.1723 | 1.1058 | 3.0853 | |
| BT-549 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 2.67 | uM | 5909.085 | 1.1740 | 1.1067 | 3.0853 | |
| BT-549 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 13.3 | uM | 5909.085 | 1.0980 | 1.0615 | 3.0853 | |
| BT-549 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 66.7 | uM | 5909.085 | 0.8512 | 0.8983 | 3.0853 | |
| BT-549 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 333 | uM | 5909.085 | 1.3742 | 1.2171 | 3.0853 | |
| BT-549 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00256 | uM | 5910.084 | 1.0030 | 1.0019 | 3.1096 | |
| BT-549 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0128 | uM | 5910.084 | 1.0922 | 1.0575 | 3.1096 | |
| BT-549 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.064 | uM | 5910.084 | 1.0703 | 1.0442 | 3.1096 | |
| BT-549 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.32 | uM | 5910.084 | 1.1521 | 1.0932 | 3.1096 | |
| BT-549 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1.6 | uM | 5910.084 | 1.2058 | 1.1241 | 3.1096 | |
| BT-549 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 8 | uM | 5910.084 | 1.0899 | 1.0561 | 3.1096 | |
| BT-549 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 40 | uM | 5910.084 | 1.1073 | 1.0666 | 3.1096 | |
| BT-549 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 200 | uM | 5910.084 | 0.4530 | 0.5504 | 3.1096 | |
| BT-549 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1000 | uM | 5910.084 | 0.4623 | 0.5606 | 3.1096 | |
| CAMA-1 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00256 | uM | 5911.084 | 0.9764 | 0.9540 | 1.0262 | |
| CAMA-1 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0128 | uM | 5911.084 | 0.9973 | 0.9947 | 1.0262 | |
| CAMA-1 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.064 | uM | 5911.084 | 0.9894 | 0.9793 | 1.0262 | |
| CAMA-1 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.32 | uM | 5911.084 | 1.0135 | 1.0262 | 1.0262 | |
| CAMA-1 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1.6 | uM | 5911.084 | 0.9445 | 0.8918 | 1.0262 | |
| CAMA-1 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 8 | uM | 5911.084 | 0.9349 | 0.8730 | 1.0262 | |
| CAMA-1 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 40 | uM | 5911.084 | 0.4806 | -0.0207 | 1.0262 | |
| CAMA-1 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 200 | uM | 5911.084 | 0.1127 | -0.7616 | 1.0262 |